BST-CarGel® Treatment Maintains Cartilage Repair Superiority over Microfracture at 5 Years in a Multicenter Randomized Controlled Trial.
Matthew S. Shive,William D. Stanish,Robert G. McCormack,Francisco Forriol,Nicholas G. H. Mohtadi,Stéphane Pelet,Jacques Desnoyers,Stéphane Méthot,Kendra Vehik,Alberto Restrepo +9 more
Reads0
Chats0
TLDR
BST-CarGel® was shown to be an effective mid-term cartilage repair treatment and resulted in sustained and significantly superior repair tissue quantity and quality over microfracture alone at 5 years.Abstract:
ObjectiveThe efficacy and safety of BST-CarGel®, a chitosan scaffold for cartilage repair was compared with microfracture alone at 1 year during a multicenter randomized controlled trial in the knee. This report was undertaken to investigate 5-year structural and clinical outcomes.DesignThe international randomized controlled trial enrolled 80 patients, aged 18 to 55 years, with grade III or IV focal lesions on the femoral condyles. Patients were randomized to receive BST-CarGel® treatment or microfracture alone, and followed standardized 12-week rehabilitation. Co-primary endpoints of repair tissue quantity and quality were evaluated by 3-dimensional MRI quantification of the degree of lesion filling (%) and T2 relaxation times. Secondary endpoints were clinical benefit measured with WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) questionnaires and safety. General estimating equations were used for longitudinal statistical analysis of repeated measures.ResultsBlinded MRI analysis ...read more
Citations
More filters
Journal ArticleDOI
Surgical and tissue engineering strategies for articular cartilage and meniscus repair.
Heenam Kwon,Wendy E. Brown,Cassandra A. Lee,Dean Wang,Nikolaos K. Paschos,Jerry C. Hu,Kyriacos A. Athanasiou +6 more
TL;DR: Surgical techniques, including tissue-engineered products, that are currently in clinical use, as well as a discussion of state-of-the-art tissue engineering strategies and technologies that are being developed for use in articular cartilage and meniscus repair and regeneration are provided.
Journal ArticleDOI
Chitosan as a Wound Dressing Starting Material: Antimicrobial Properties and Mode of Action
TL;DR: The antimicrobial properties of chitosan are reviewed and the mechanisms of action toward microbial cells as well as the interactions with mammalian cells in terms of wound healing process are described.
Journal ArticleDOI
Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture Two-Year Follow-up of a Prospective Randomized Trial
Daniel B.F. Saris,Andrew Price,Wojciech Widuchowski,Marion Bertrand-Marchand,Jacob Caron,Jon Olav Drogset,Pieter J. Emans,Ales Podskubka,A.I. Tsuchida,Sven Kili,David W. Levine,Mats Brittberg +11 more
TL;DR: The treatment of symptomatic cartilage knee defects ≥3 cm2 in size using MACI was clinically and statistically significantly better than with MFX, with similar structural repair tissue and safety, in this heterogeneous patient population.
Effects of calcified cartilage on healing of chondral defects treated with microfracture in horses
TL;DR: Close arthroscopic visualization is recommended for debridement of clinical lesions to ensure removal of the calcified cartilage layer, which appears to provide optimal amount and attachment of repair tissue.
Journal ArticleDOI
Autologous chondrocyte implantation in the knee: systematic review and economic evaluation.
Hema Mistry,Martin Connock,Joshua Pink,Deepson Shyangdan,Christine Clar,Pamela Royle,Rachel Court,Leela C Biant,Andrew J. Metcalfe,Norman Waugh +9 more
TL;DR: Economic modelling suggested that ACI was cost-effective compared with MF across a range of scenarios, and survival analysis suggests that long-term results are better with ACI than with MF.
References
More filters
Journal Article
Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee.
TL;DR: WOMAC is a disease-specific purpose built high performance instrument for evaluative research in osteoarthritis clinical trials and fulfil conventional criteria for face, content and construct validity, reliability, responsiveness and relative efficiency.
Journal ArticleDOI
SF-36 health survey update.
TL;DR: The SF-36 (Medical Outcomes Trust, Boston, MA) is a multipurpose, short-form health survey with only 36 questions, which yields an eight-scale profile of scores as well as physical and mental health summary measures as mentioned in this paper.
Journal ArticleDOI
Chitosan chemistry and pharmaceutical perspectives.
TL;DR: Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S. S. Nagar, Punjab-160 062, India, Institute of Biochemistry, Faculty of Medicine, Polytechnic University, Via Ranieri 67, IT-60100 Ancona, Italy, and Department of Medicinal Chemistry & Natural Products,The Hebrew University of Jerusalem, School of Pharmacy-Faculty of medicine, Jerusalem 91120, Israel.
Journal ArticleDOI
Novel injectable neutral solutions of chitosan form biodegradable gels in situ
Abdellatif Chenite,C Chaput,Dadong Wang,C Combes,Michael D. Buschmann,Caroline D. Hoemann,Jean-Christophe Leroux,B.L Atkinson,F Binette,A Selmani +9 more
TL;DR: This study reports for the first time the use of polymer/polyol salt aqueous solutions as gelling systems, suggesting the discovery of a prototype for a new family of thermosetting gels highly compatible with biological compounds.